Research progress of metabotropic glutamate receptor 5 in related central nervous system diseases

ZHU Enni; WU Chaoran; LIAO Hong

doi:10.11665/j.issn.1000-5048.20210614

Journal of China Pharmaceutical University > 2021 > 52(6): 751-758. > DOI: 10.11665/j.issn.1000-5048.20210614

ZHU Enni, WU Chaoran, LIAO Hong. Research progress of metabotropic glutamate receptor 5 in related central nervous system diseases[J]. Journal of China Pharmaceutical University, 2021, 52(6): 751-758. DOI: 10.11665/j.issn.1000-5048.20210614

Citation:

PDF (1052 KB)

Research progress of metabotropic glutamate receptor 5 in related central nervous system diseases

New Drug Screening Center,Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing 210009, China

Funds: This study was supported by the National Natural Science Foundation of China (No.82073831)

More Information

Received Date: May 06, 2021
Revised Date: October 25, 2021

Graphical Abstract

Abstract

Abstract

As a key component of glutamatergic system, metabotropic glutamate receptor 5 (mGluR5) has been extensively involved in the regulation of physiological processes such as synaptic transmission, synaptic plasticity and synaptic excitation/inhibition balance.Over the past few decades, mGluR5 has been found to be closely related to multiple neurological and psychiatric disorders, thus it is of considerable interest as a drug target in the treatment of such disorders.This review summarizes the structure and distribution of mGluR5, its normal physiological function, its pathological roles in related central nervous system (CNS) diseases, as well as the current status of its drug development, in order to provide reference for further investigation.
- metabotropic glutamate receptor 5,
- physiological function,
- central nervous system diseases,
- drug development,
- advances

FullText(HTML)

References (59)

References

[1]	. Pharmacol Ther，2014，142（3）：281-305.
[2]	Reiner A，Levitz J. Glutamatergic signaling in the central nervous system：ionotropic and metabotropic receptors in concert［J］. Neuron，2018，98（6）：1080-1098.
[3]	Niswender CM，Conn PJ. Metabotropic glutamate receptors：physiology，pharmacology，and disease［J］. Annu Rev Pharmacol Toxicol，2010，50：295-322.
[4]	Ellaithy A，Gonzalez-Maeso J，Logothetis DA，et al. Structural and biophysical mechanisms of class C G protein-coupled receptor function［J］. Trends Biochem Sci，2020，45（12）：1049-1064.
[5]	Sun W，McConnell E，Pare JF，et al. Glutamate-dependent neuroglial calcium signaling differs between young and adult brain［J］. Science，2013，339（6116）：197-200.
[6]	Planas-Fontanez TM，Dreyfus CF，Saitta KS. Reactive astrocytes as therapeutic targets for brain degenerative diseases：roles played by metabotropic glutamate receptors［J］. Neurochem Res，2020，45（3）：541-550.
[7]	Sengmany K，Gregory KJ. Metabotropic glutamate receptor subtype 5：molecular pharmacology，allosteric modulation and stimulus bias［J］. Br J Pharmacol，2016，173（20）：3001-3017.
[8]	Eng AG，Kelver DA，Hedrick TP，et al. Transduction of group I mGluR-mediated synaptic plasticity by beta-arrestin2 signalling［J］. Nat Commun，2016，7：13571.
[9]	Luscher C，Huber KM. Group 1 mGluR-dependent synaptic long-term depression：mechanisms and implications for circuitry and disease［J］. Neuron，2010，65（4）：445-459.
[10]	Shiraishi-Yamaguchi Y，Furuichi T. The Homer family proteins［J］. Genome Biol ，2007，8（2）：206.
[11]	Holz A，Mulsch F，Schwarz MK，et al. Enhanced mGlu5 signaling in excitatory neurons promotes rapid antidepressant effects via AMPA receptor activation［J］. Neuron，2019，104（2）：338-352.
[12]	Ribeiro FM，Vieira LB，Pires RG，et al. Metabotropic glutamate receptors and neurodegenerative diseases［J］. Pharmacol Res，2017，115：179-191.
[13]	Bagni C，Zukin RS. A Synaptic perspective of fragile X syndrome and autism spectrum disorders［J］. Neuron，2019，101（6）：1070-1088.
[14]	Bruno V，Caraci F，Copani A，et al. The impact of metabotropic glutamate receptors into active neurodegenerative processes：a "dark side" in the development of new symptomatic treatments for neurologic and psychiatric disorders［J］. Neuropharmacology，2017，115：180-192.
[15]	Pereira V，Goudet C. Emerging trends in pain modulation by metabotropic glutamate receptors［J］. Front Mol Neurosci，2018，11：464.
[16]	Hagerman RJ，Berry-Kravis E，Hazlett HC，et al. Fragile X syndrome［J］. Nat Rev Dis Primers，2017，3：17065.
[17]	Prieto M，Folci A，Martin S. Post-translational modifications of the fragile X mental retardation protein in neuronal function and dysfunction［J］. Mol Psychiatry，2020，25（8）：1688-1703.
[18]	Huber KM，Gallagher SM，Warren ST，et al. Altered synaptic plasticity in a mouse model of fragile X mental retardation［J］. Proc Natl Acad Sci U S A，2002，99（11）：7746-7750.
[19]	Gross C，Chang CW，Kelly SM，et al. Increased expression of the PI3K enhancer PIKE mediates deficits in synaptic plasticity and behavior in fragile X syndrome［J］. Cell Rep，2015，11（5）：727-736.
[20]	Aloisi E，Le Corf K，Dupuis J，et al. Altered surface mGluR5 dynamics provoke synaptic NMDAR dysfunction and cognitive defects in Fmr1 knockout mice［J］. Nat Commun，2017，8（1）：1103.
[21]	Guo W，Molinaro G，Collins KA，et al. Selective disruption of metabotropic glutamate receptor 5-Homer interactions mimics phenotypes of fragile X syndrome in mice［J］. J Neurosci，2016，36（7）：2131-2147.
[22]	Higashimori H，Morel L，Huth J，et al. Astroglial FMRP-dependent translational down-regulation of mGluR5 underlies glutamate transporter GLT1 dysregulation in the fragile X mouse［J］. Hum Mol Genet，2013，22（10）：2041-2054.
[23]	Men YQ，Ye L，Risgaard RD，et al. Astroglial FMRP deficiency cell-autonomously up-regulates miR-128 and disrupts developmental astroglial mGluR5 signaling［J］. Proc Natl Acad Sci U S A，2020，117（40）：25092-25103.
[24]	Muller UC，Deller T，Korte M. Not just amyloid：physiological functions of the amyloid precursor protein family［J］. Nat Rev Neurosci，2017，18（5）：281-298.
[25]	Benarroch EE. Glutamatergic synaptic plasticity and dysfunction in Alzheimer disease：emerging mechanisms［J］. Neurology，2018，91（3）：125-132.
[26]	Westmark CJ. Fragile X and APP：a decade in review，a vision for the future［J］. Mol Neurobiol，2019，56（6）：3904-3921.
[27]	Hu NW，Nicoll AJ，Zhang DN，et al. mGlu5 receptors and cellular prion protein mediate amyloid-beta-facilitated synaptic long-term depression in vivo［J］. Nat Commun，2014，5：3374.
[28]	Hamilton A，Vasefi M，Vander Tuin C，et al. Chronic pharmacological mGluR5 inhibition prevents cognitive impairment and reduces pathogenesis in an Alzheimer disease mouse model［J］. Cell Rep，2016，15（9）：1859-1865.
[29]	Abd-Elrahman KS，Hamilton A，Albaker A，et al. mGluR5 contribution to neuropathology in Alzheimer mice is disease stage-dependent［J］. ACS Pharmacol Transl Sci，2020，3（2）：334-344.
[30]	Doria JG，de Souza JM，Silva FR，et al. The mGluR5 positive allosteric modulator VU0409551 improves synaptic plasticity and memory of a mouse model of Huntington''s disease［J］. J Neurochem，2018，147（2）：222-239.
[31]	Abd-Elrahman KS，Ferguson SSG. Modulation of mTOR and CREB pathways following mGluR5 blockade contribute to improved Huntington''s pathology in zQ175 mice［J］. Mol Brain，2019，12（1）：35.
[32]	Zhang Z，Zhang S，Fu P，et al. Roles of glutamate receptors in Parkinson''s disease［J］. Int J Mol Sci，2019，20（18）：4391.
[33]	Bonifacino T，Provenzano F，Gallia E，et al. In-vivo genetic ablation of metabotropic glutamate receptor type 5 slows down disease progression in the SOD1（G93A） mouse model of amyotrophic lateral sclerosis［J］. Neurobiol Dis，2019，129：79-92.
[34]	Murrough JW，Abdallah CG，Mathew SJ. Targeting glutamate signalling in depression：progress and prospects［J］. Nat Rev Drug Discov，2017，16（7）：472-486.
[35]	Wagner KV，Hartmann J，Labermaier C，et al. Homer1/mGluR5 activity moderates vulnerability to chronic social stress［J］. Neuropsychopharmacol，2015，40（5）：1222-1233.
[36]	Esterlis I，Holmes SE，Sharma P，et al. Metabotropic glutamatergic receptor 5 and stress disorders：knowledge gained from receptor imaging studies［J］. Biol Psychiatry，2018，84（2）：95-105.
[37]	Deschwanden A，Karolewicz B，Feyissa AM，et al. Reduced metabotropic glutamate receptor 5 density in major depression determined by ［（11）C］ABP688 PET and postmortem study［J］. Am J Psychiatry，2011，168（7）：727-734.
[38]	Davis MT，Hillmer A，Holmes SE，et al. In vivo evidence for dysregulation of mGluR5 as a biomarker of suicidal ideation［J］. Proc Natl Acad Sci U S A，2019，116（23）：11490-11495.
[39]	Shin S，Kwon O，Kang JI，et al. mGluR5 in the nucleus accumbens is critical for promoting resilience to chronic stress［J］. Nat Neurosci，2015，18（7）：1017-1024.
[40]	Hefti K，Holst SC，Sovago J，et al. Increased metabotropic glutamate receptor subtype 5 availability in human brain after one night without sleep［J］. Biol Psychiatry，2013，73（2）：161-168.
[41]	Esterlis I，DellaGioia N，Pietrzak RH，et al. Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response：an ［（11）C］ABP688 and PET imaging study in depression［J］. Mol Psychiatry，2018，23（4）：824-832.
[42]	Birnbaum R，Weinberger DR. Genetic insights into the neurodevelopmental origins of schizophrenia［J］. Nat Rev Neurosci，2017，18（12）：727-740.
[43]	Jorratt P，Hoschl C，Ovsepian SV. Endogenous antagonists of N-methyl-d-aspartate receptor in schizophrenia［J］. Alzheimers Dement，2021，17（5）：888-905.
[44]	Goff DC. D-cycloserine in schizophrenia：new strategies for improving clinical outcomes by enhancing plasticity［J］. Curr Neuropharmacol，2017，15（1）：21-34.
[45]	Geddes AE，Huang XF，Newell KA. Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia［J］. Prog Neuropsychopharmacol Biol Psychiatry，2011，35（4）：896-904.
[46]	Matta JA，Ashby MC，Sanz-Clemente A，et al. mGluR5 and NMDA receptors drive the experience- and activity-dependent NMDA receptor NR2B to NR2A subunit switch［J］. Neuron，2011，70（2）：339-351.
[47]	Barnes SA，Pinto-Duarte A，Kappe A，et al. Disruption of mGluR5 in parvalbumin-positive interneurons induces core features of neurodevelopmental disorders［J］. Mol Psychiatry，2015，20（10）：1161-1172.
[48]	Wang HY，MacDonald ML，Borgmann-Winter KE，et al. mGluR5 hypofunction is integral to glutamatergic dysregulation in schizophrenia［J］. Mol Psychiatry，2020，25（4）：750-760.
[49]	Matosin N，Newell KA. Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia［J］. Neurosci Biobehav Rev，2013，37（3）：256-268.
[50]	Ghoshal A，Moran SP，Dickerson JW，et al. Role of mGlu₅ receptors and inhibitory neurotransmission in M₁ dependent muscarinic LTD in the prefrontal cortex：implications in schizophrenia［J］. ACS Chem Neurosci，2017，8（10）：2254-2265.
[51]	Balu DT，Li Y，Takagi S，et al. An mGlu5-positive allosteric modulator rescues the neuroplasticity deficits in a genetic model of NMDA receptor hypofunction in schizophrenia［J］. Neuropsychopharmacology，2016，41（8）：2052-2061.
[52]	Dore AS，Okrasa K，Patel JC，et al. Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain［J］. Nature，2014，511（7511）：557-562.
[53]	Hellyer S，Leach K，Gregory KJ. Neurobiological insights and novel therapeutic opportunities for CNS disorders from mGlu receptor allosteric and biased modulation［J］. Curr Opin Pharmacol，2017，32：49-55.
[54]	Pillai RL，Tipre DN. Metabotropic glutamate receptor 5-a promising target in drug development and neuroimaging［J］. Eur J Nucl Med Mol Imaging，2016，43（6）：1151-1170.
[55]	Xu Y，Li Z. Imaging metabotropic glutamate receptor system：application of positron emission tomography technology in drug development［J］. Med Res Rev，2019，39（5）：1892-1922.
[56]	Mecca AP，McDonald JW，Michalak HR，et al. PET imaging of mGluR5 in Alzheimer''s disease［J］. Alzheimers Res Ther，2020，12（1）：15.
[57]	Brasic JR，Nandi A，Russell DS，et al. Cerebral expression of metabotropic glutamate receptor subtype 5 in idiopathic autism spectrum disorder and fragile X syndrome：a pilot study［J］. Int J Mol Sci，2021，22（6）：2863.
[58]	Streffer J，Treyer V，Buck A，et al. Regional brain mGlu5 receptor occupancy following single oral doses of mavoglurant as measured by ［（11）C］-ABP688 PET imaging in healthy volunteers［J］. Neuroimage，2021，230：117785.
[59]	Berry-Kravis E，Hessl D，Coffey S，et al. A pilot open label，single dose trial of fenobam in adults with fragile X syndrome［J］. J Med Genet，2009，46（4）：266-271.

Cited By

Cited by

Periodical cited type(6)

1.	金伟斌，陈礼峰，唐倩倩，顾晓风. 顶空气相色谱法测定生脉注射液中甲醛和乙醛的含量. 中国合理用药探索. 2022(06): 115-120 .
2.	李浩宇，唐宝强，何东升，涂家生. 气相色谱法测定药用辅料聚西托醇1000中的残留杂质. 中国药科大学学报. 2022(03): 293-299 . 本站查看
3.	王贺，钱利武，阚红卫. 药用辅料监管法规、质量标准现状分析及应对措施. 中南药学. 2022(08): 1937-1941 .
4.	庞丽然，贺丞，杜力，刘国芳. 重组蛋白中吐温80含量硫氰酸铵钴显色检测法的改进及验证. 中国生物制品学杂志. 2021(09): 1111-1113+1119 .
5.	郑永强，付俊伟，朱慧敏，陶晓军. 一种用于实现脑靶向的负载长春新碱抗肿瘤纳米药物制剂的制备及表征. 肿瘤药学. 2021(05): 547-553 .
6.	黄婧，吴宏伟. 依诺沙星滴眼液辅料及药包材相容性研究. 中国现代应用药学. 2021(22): 2802-2806 .

Other cited types(2)

Get Citation

PDF

XML

Article views (230) PDF downloads (737) Cited by(8)

Turn off MathJax

Article Contents

Abstract

References

Research progress of metabotropic glutamate receptor 5 in related central nervous system diseases

Abstract

References

Cited by

Periodical cited type(6)

Other cited types(2)

Catalog

Export File

Citation

Format

Content